values for fecal microbiota composition in relation to dietary lactose (grams/day) in congenital chloride diarrhea (CLD; n = 22) and healthy controls (n = 19). of the subjects, and (B) only in the samples taken at the study entry. The number of CLD samples in the final microbiota analyses and taken during the standard treatment were: 22 (time point 0, baseline), 23 (time point 1 week), 21 (time point 2 weeks), and 23 (time point 3 weeks). During the butyrate trial, fecal microbiota were further analyzed from 14 (time point 4 weeks), 12 (time point 5 weeks), and 14 (time point 6 weeks) samples.(TIFF) pone.0269561.s004.tiff (7.8M) GUID:?880BD69B-26BA-42C9-86A2-AD6FC223F781 S3 Fig: Comparison of gut microbiota between the subjects with the lowest levels of calprotectin ( 50 ug/g) in different groups. Shown are (A) Principal-coordinated Analysis (PcoA) based on Bray-Curtis dissimilarities of the richness of the microbiota, and (B) clustered stacked column graphs demonstrating microbiota differences at the genus level. The clusters in (A) are shown by circles, which were drawn based on the standard deviations of the data points in each category of the samples (CD, Crohns disease; CLD, Congenital chloride diarrhea; Healthy).(TIFF) pone.0269561.s005.tiff (2.4M) GUID:?1C69D3C8-222D-4FD3-9909-518CCDD4AE75 S4 Fig: Comparison of gut microbiota between the subjects with CLD at each data points. Shown are Principal-coordinated Analysis (PcoA) based on Bray-Curtis dissimilarities Midodrine hydrochloride of the richness of the microbiota at the study entry (time point 0) and further during the standard salt substitution (time points 1, 2, and 3 weeks), and during the butyrate trial (time points 4, 5, and 6 weeks).(TIFF) pone.0269561.s006.tiff (9.4M) GUID:?7B10DA6D-BDCC-4371-980B-1471B5165DF4 S5 Fig: Covariate plots showing fecal microbiota composition before the butyrate trial (time point 3 weeks), and as measured once a week during the butyrate trial (time points 4, 5, and 6 weeks) in the subjects with congenital chloride diarrhea (CLD). Shown are microbiota composition for the taxa with significant differences (P 0.01) (CovariateTest) between the first and last measurement (time point 3 vs 6). Comparable data for is usually shown in Fig 5B of the main article. Lines define group means and shaded areas 95% confidence intervals.(TIFF) pone.0269561.s007.tiff (21M) GUID:?BB2DD0FB-91F6-4053-A2F9-7B03EA8D9351 S6 Fig: Gastrointestinal (GI) symptoms of the study subjects (n = 30) during the study. Treatment group indicates the group of subjects who attended the 3-week butyrate trial. No treatment defines the group with the standard salt substitution therapy and follow-up period of 3 weeks. Lines define the imply values and whiskers standard deviations.(TIFF) pone.0269561.s008.tiff (7.4M) GUID:?946D1911-503B-4BCC-BA2E-85C5776AE99D S7 Fig: Midodrine hydrochloride Fecal biomarker levels in individuals with congenital chloride diarrhea (CLD) treated with butyrate. Line graphs show biomarker levels from your baseline to 6 weeks at the end of the follow-up period. Data are offered as mean with standard errors of mean. PIK3R5 IAP, intestinal alkaline phosphatase. MG-H1, methylglyoxal-hydro-imidazolone. Shaded areas define samples taken during the butyrate treatment.(TIFF) pone.0269561.s009.tiff (11M) GUID:?C2DE4260-103B-4F36-B455-A3197884EE70 S8 Fig: Shown are microbiota composition for Faecalibacterium in each category of the samples (CD, Crohns disease; CLD IBD, Congenital chloride diarrhea and inflammatory bowel disease; CLD, Congenital chloride diarrhea; Healthy). Data are offered as group means and standard errors of the mean.(TIFF) pone.0269561.s010.tiff (33M) GUID:?3A01C30A-665A-4C2C-9D4C-EB79AA94AA0D S1 Table: Characteristics of the subjects and laboratory values at the study access. (PDF) pone.0269561.s011.pdf (29K) GUID:?1BE96E1F-DBD7-4D6B-9B0F-7AEF6C7622F1 S2 Table: Differences in richness and diversity of fecal microbiota between the groups. (PDF) pone.0269561.s012.pdf (24K) GUID:?1EDC8C54-AD6F-4598-8698-5F6D3D31FC95 S3 Table: Microbiota differences. values for microbiota differences in congenital chloride diarrhea (CLD), CLD-associated IBD (CLD IBD), and Crohns disease (CD), in comparison with the microbiota of healthy controls (n = 19). Shown are only the taxa with adjusted values (FDR_p) 0.1 after comparison of the subgroup (CD, CLD IBD, or CLD) and healthy controls (GroupTest).(PDF) pone.0269561.s013.pdf (33K) GUID:?8E071441-3118-48D5-A21F-3211758E8F64 S4 Table: Nutrient intake. Daily intakes of energy and energy-yielding nutrients in patients with congenital chloride diarrhea (CLD; n = 30). Values outside the research range are shown bolded.(PDF) pone.0269561.s014.pdf (26K) GUID:?9FC988A6-4AA7-4E56-A514-1466D1C19013 S5 Table: Vitamins, minerals and trace elements. Daily intakes of vitamins, minerals and trace elements in patients with congenital chloride diarrhea (CLD; n = 30). Values outside the research range are shown bolded.(PDF) pone.0269561.s015.pdf Midodrine hydrochloride (30K) GUID:?F8A15166-0C6A-4AD3-ACEF-2EC1BE3866B8 S6 Table: Midodrine hydrochloride Microbiota and lactose intake. values for fecal microbiota composition in relation to dietary lactose (grams/day) in congenital chloride diarrhea (CLD; n = 22) and healthy controls (n = 19). Shown are only the taxa with adjusted values (FDR) 0.1 (CovariateTest). p, value. FDR, adjusted value after Benjamini-Hochberg correction.(PDF) pone.0269561.s016.pdf (15K) GUID:?FAB28F5A-C422-4098-BB56-AC315C8E4578 S7 Table: Microbiota and fiber Midodrine hydrochloride intake. values for fecal microbiota composition in relation to dietary total fiber (grams/day) in congenital chloride diarrhea (CLD; n = 22) and healthy controls (n = 19). Shown are only the taxa with.
